Key Highlights
- Shares are up 10.69% pre-market to $3.83, building on a prior close of $3.46.
- The company regained full global rights to all GABAB positive allosteric modulator Assets discovered under its research collaboration with Indivior.
- The reversion followed Indivior's Research and Development rationalization and its parent company's planned Merger with Supernus Pharmaceuticals.
Addex Therapeutics (NASDAQ:ADXN) shares are up 10.69% pre-market to $3.83, building on a prior close of $3.46, after the company announced it has regained full global rights to all GABAB positive allosteric modulator assets discovered under its research collaboration with Indivior. The reversion follows Indivior's rationalization of its research and development activities and the announced merger of Indivior's Parent Company with Supernus Pharmaceuticals.
The returned rights give the company full ownership of a development candidate for substance use disorders and the freedom to pursue additional therapeutic indications beyond those originally contemplated under the collaboration agreement. Combined with its wholly owned GABAB program for chronic cough, the company now holds one of the broadest portfolios targeting GABAB receptor biology, with potential applications spanning substance use disorders, chronic cough, pain, overactive bladder, and neurodevelopmental disorders.
The Science Behind the Portfolio
GABA is the main inhibitory neurotransmitter in the nervous system, acting through receptor classes including the GABAB receptor, which plays an important role in regulating neuronal excitability. The therapeutic potential of GABAB activation has been clinically demonstrated by an existing approved drug for spasticity, but its broader use is constrained by sedation and other central nervous system side effects. Positive allosteric modulators offer an alternative approach, binding to a distinct site to enhance the receptor's natural response rather than directly activating it, which is intended to preserve more normal signaling patterns and potentially improve tolerability.
Flexibility to Advance Independently
The company's CEO said the reversion gives it the flexibility to advance its broader GABAB portfolio on its own, including evaluating new strategic partnerships in the near term or advancing the programs further before partnering. The company's lead drug candidate, dipraglurant, remains a separate Phase 2-ready asset under evaluation for brain injury recovery, including post-stroke and traumatic brain injury recovery.
A Broader Pipeline Beyond GABAB
Beyond its GABAB programs, the company holds a 20% Equity interest in a private spin-out company advancing additional allosteric modulator programs for schizophrenia and mood disorders, along with an Investment in a separate Swiss company pursuing precision medicine approaches for neurodevelopmental and neuropsychiatric disorders.






Please wait processing your request...